Recent Updates
Recently added Catalysts
PLRX

Pliant Therapeutics to Participate in Needham Healthcare Conference

Key Takeaway: SOUTH SAN FRANCISCO, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D
Price reaction · baseline $7.41 (2022-04-04 close) · hit after-hours · clean, no other PLRX news in the window
day 0 close · peak
-2.8%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+47%
120-day peak, hindsight
Typical move
1.5%
average across 6 past catalysts
Cash runway
~37 mo
Minimal dilution risk
Lead asset
PLN-101095
Phase 1 · Advanced or Metastatic Solid Tumor

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in a fireside chat as part of the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 2:15 p.m. ET.
Interested parties can access the fireside chat from the Investor Relations’ Events & Presentation page of Pliant’s website at https://ir.pliantrx.com/news-and-events/events-and-presentations with an audio archive available for 30 days from the time they are made available.
About Pliant Therapeutics, Inc.
Investor and Media Contact:
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
Last updated: Apr 5, 2022